The FDA adverse-event record for monkey

Monkey Adverse Event Insights

The FDA Center for Veterinary Medicine database holds 50 adverse event reports for Monkey, distributed across 3 distinct breeds currently tracked in the system. Of those reports, 8 involved a death outcome, producing a 16.0% case-fatality rate among reported events, which reflects reporting severity bias rather than true population mortality. These figures are aggregated directly from openFDA's Animal & Veterinary Adverse Events endpoint and update as new voluntary submissions flow through pet owners, veterinarians, and drug manufacturers.

The most frequently reported clinical signs for Monkey are Lack of efficacy - NOS (13 reports), Injection site swelling (8 reports), INEFFECTIVE, ANESTHESIA (6 reports), Bradycardia (4 reports), with Lack of efficacy - NOS leading the reaction traffic at 13 submissions. On the product side, Ketamine Hydrochloride is the single most-referenced drug with 16 reports, followed by Ketamine Hcl (9), Desoxycorticosterone Pivalate (7), Isoflurane (5). This combination surfaces which therapeutic classes generate the most adverse event chatter for this species, a useful starting point when comparing Monkey reporting patterns against other companion animals in the dataset.

Of the 33 Monkey reports with a coded outcome, Recovered/Normal accounts for the largest share at 57.6%. Annual submission volume spans 2,010 to 2,024 reports across the 14 years on file, a range that reflects evolving owner awareness, veterinary reporting habits, and new product approvals rather than stable underlying incidence. The breed-level table below breaks these patterns down further, showing how the 3 tracked monkey breeds compare on volume, deaths, and average age at report. As with all FDA adverse event data, correlation is the ceiling, causation requires clinical investigation beyond what these aggregates can provide.